Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067191 | 0.89 | CNR2 (0.35) | CNR1CNR2 | |
| SCHEMBL29444825 | 0.89 | CNR2 (0.35) | CNR1CNR2 | |
| SCHEMBL126380 | 0.86 | DHFR (0.37) | — | |
| SCHEMBL12722133 | 0.84 | CNR2 (0.36) | MAPTCRHR1CNR1CNR2 | |
| SCHEMBL29555023 | 0.84 | CYP2C9 (0.33) | — | |
| SCHEMBL10066719 | 0.84 | CYP2C9 (0.33) | — | |
| SCHEMBL124626 | 0.84 | NR1H2 (0.33) | — | |
| SCHEMBL25569218 | 0.84 | CNR1 (0.31) | CNR1CNR2 | |
| SCHEMBL19473640 | 0.83 | CNR1 (0.32) | CNR1CNR2 | |
| SCHEMBL10038732 | 0.83 | PDE2A (0.33) | PDE2ATP53MAPTUTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120056165-A1 | ORGANIC LUMINESCENT MEDIUM | IDEMITSU KOSAN CO., LTD. | 2012-03-08 | — | — | US | disclosed |
| US-20120013244-A1 | ORGANIC LUMINESCENT MEDIUM | IDEMITSU KOSAN CO., LTD. | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120013244-A1 | ORGANIC LUMINESCENT MEDIUM | ANXA1, ANXA11, GLB1 | PDE2A 2186/4885TP53 350/4885MAPT 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.